BNP Paribas Financial Markets Boosts Stake in Twist Bioscience Co. (NASDAQ:TWST)

BNP Paribas Financial Markets grew its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 128.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,032 shares of the company’s stock after purchasing an additional 21,357 shares during the period. BNP Paribas Financial Markets owned approximately 0.06% of Twist Bioscience worth $1,718,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of TWST. Signaturefd LLC lifted its position in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the last quarter. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience during the second quarter valued at about $43,000. Blue Trust Inc. raised its stake in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience in the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TWST. Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Robert W. Baird boosted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. TD Cowen reissued a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Scotiabank lifted their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Finally, Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Insider Transactions at Twist Bioscience

In related news, SVP Paula Green sold 3,310 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $143,025.10. Following the transaction, the senior vice president now owns 84,585 shares in the company, valued at $3,654,917.85. The trade was a 3.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Adam Laponis sold 856 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the sale, the chief financial officer now directly owns 73,397 shares of the company’s stock, valued at $3,068,728.57. The trade was a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is currently owned by corporate insiders.

Twist Bioscience Stock Performance

TWST stock opened at $52.70 on Friday. Twist Bioscience Co. has a fifty-two week low of $24.81 and a fifty-two week high of $60.90. The company’s 50 day moving average price is $44.36 and its 200 day moving average price is $46.41. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of -14.64 and a beta of 1.82.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.